TAVI: Good Outcomes with Intermediate Risk

Original Title: Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement in Intermediate-Risk Patients: A Propensity Score Analysis. Reference: Vinod H Thourani et al. Lancet Published Online April 3, 2016. Courtesy of Dr. Carlos Fava. The transcatheter Aortic Valve Replacement (TAVI) has shown benefits in high risk patients or inoperable patients, but there is little evidence<a href="https://solaci.org/en/2016/04/13/tavi-good-outcomes-with-intermediate-risk/" title="Read more" >...</a>

TAVI in ≥90 year old patients: as beneficial as in younger patients

Original Title: Should Transcatheter Aortic valve replacement Be Performed in Nonagenarians? Insights from the STS/ACC TVT Registry. Reference: Mani Arsalan et al. J Am Coll Cardiol. 2016 Mar 29;67(12):1387-95. Courtesy of Dr. Carlos Fava The benefit of the transcatheter aortic valve replacement (TAVI) has already been shown in the general population undergoing this procedure. The number<a href="https://solaci.org/en/2016/04/12/tavi-in-%e2%89%a590-year-old-patients-as-beneficial-as-in-younger-patients/" title="Read more" >...</a>

New York TAVR Registry: Trends in use and mortality at one year

Original Title: Utilization and 1-Year Mortality for Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement in New York Patients With Aortic Stenosis2011 to 2012. Reference:Hannan EL et al. J Am CollCardiolIntv. 2016;9(6):578-585. Courtesy of Dr. Agustín Vecchia It’s been only 14 years sinceCribierperformed the first transcatheter valve replacement. Today, during 2016, 100,000 patients are expected to<a href="https://solaci.org/en/2016/04/08/new-york-tavr-registry-trends-in-use-and-mortality-at-one-year/" title="Read more" >...</a>

PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with severe symptomatic aortic stenosis. For those that can be accessedfemorally, TAVI seems even better than surgery. In all, 2032 intermediate risk patients were randomized in 57 centers to TAVI with Sapien<a href="https://solaci.org/en/2016/04/08/partner-2a-tavi-not-inferior-to-surgery-in-intermediate-risk-patients/" title="Read more" >...</a>

PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox

A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, compared to younger patients. In fact, patients over 90 undergoing TAVI have the same life expectation of someone the same age with no aortic stenosis. In-hospital<a href="https://solaci.org/en/2016/04/08/partner-1-in-90-year-old-patients-tavi-and-the-age-paradox/" title="Read more" >...</a>

Atrial Fibrillation: Important Impact on TAVI

Original Title: Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial. Reference: Angelo B. Biviano et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002766. Courtesy of Dr. Carlos Fava. The conversion to atrial fibrillation (AF) in the context of transcatheter aortic valve replacement<a href="https://solaci.org/en/2016/03/04/atrial-fibrillation-important-impact-on-tavi/" title="Read more" >...</a>

SCAI Releases Expert Consensus for Cardio-Oncology Patients Treated in Cardiac Catherization Labs

The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement providing cardiologists, oncologists and internal medicine physicians guidance for treating patients facing concomitant cardiovascular disease and cancer. The document, “SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catherization Laboratory,” was released in Catheterization and Cardiovascular Interventions (CCI),<a href="https://solaci.org/en/2016/01/19/scai-releases-expert-consensus-for-cardio-oncology-patients-treated-in-cardiac-catherization-labs/" title="Read more" >...</a>

Comparing Computed Tomography vs. Angiography to Assess Transfemoral Access for TAVI

Original Title: Transfemoral Access Assessment for Transcatheter Aortic Valve Replacement Evidence Based Application of Computed Tomography over Invasive Angiography. Reference: Circ Cardiovas Imaging 2015 DOI:10.1161/CIRCIMAGING.114.0011995. Courtesy of Dr. Guillermo Migliaro Transfemoral access for TAVI was introduced in 2006 and is considered first choice. Vascular complications (VCs) are important events that correlate to increased mortality. According to the<a href="https://solaci.org/en/2016/01/18/comparing-computed-tomography-vs-angiography-to-assess-transfemoral-access-for-tavi/" title="Read more" >...</a>

TAVI: Mobility Predicts Outcomes

Original Title: Poor Mobility Predicts Adverse Outcomes Better Than Other Frailty Indices in Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: James Cockburn, et al. Catheterization and Cardiovascular Intervention 2015;86:1271-1277 Courtesy of Dr. Carlos Fava Interventional Cardiologist Favaloro Foudation – Buenos Aires There is a group of high risk patients that are also fragile, and there is<a href="https://solaci.org/en/2015/12/17/tavi-mobility-predicts-outcomes/" title="Read more" >...</a>

Do We Need a New Classification System for Aortic Dissection?

Original Title: DISSECT: A New Approach to Categorization of Aortic Dissection. Reference: M.D. Dabe, et al. Eur J Vasc Endovasac Surg 2013;46:175-90 Courtesy of Dr. Carlos Fava Interventional Cardiologist Favaloro Foundation – Argentina Aortic dissection is a lethal disease, especially in its first stages. The current classification systems (DeBakey 1965 and Stanford 1970) are widely used<a href="https://solaci.org/en/2015/12/11/do-we-need-a-new-classification-system-for-aortic-dissection/" title="Read more" >...</a>